Literature DB >> 16820094

Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure.

Hanneke W M van Laarhoven1, Giulio Gambarota, Jasper Lok, Martin Lammens, Yvonne L M Kamm, Theo Wagener, Cornelis J A Punt, Albert J van der Kogel, Arend Heerschap.   

Abstract

For the systemic treatment of colorectal cancer, 5-fluorouracil (FU)-based chemotherapy is the standard. However, only a subset of patients responds to chemotherapy. Breathing of carbogen (95% O2 and 5% CO2) may increase the uptake of FU through changes in tumor physiology. This study aims to monitor in animal models in vivo the effects of carbogen breathing on tumor blood plasma volume, pH, and energy status, and on FU uptake and metabolism in two colon tumor models C38 and C26a, which differ in their vascular structure and hypoxic status. Phosphorus-31 magnetic resonance spectroscopy (MRS) was used to assess tumor pH and energy status, and fluorine-19 MRS was used to follow FU uptake and metabolism. Advanced magnetic resonance imaging methods using ultrasmall particles of iron oxide were performed to assess blood plasma volume. The results showed that carbogen breathing significantly decreased extracellular pH and increased tumor blood plasma volume and FU uptake in tumors. These effects were most significant in the C38 tumor line, which has the largest relative vascular area. In the C26a tumor line, carbogen breathing increased tumor growth delay by FU. In this study, carbogen breathing also enhanced systemic toxicity by FU.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820094      PMCID: PMC1601468          DOI: 10.1593/neo.06115

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  42 in total

1.  A model of blood-brain barrier permeability to water: accounting for blood inflow and longitudinal relaxation effects.

Authors:  Emmanuel L Barbier; Keith S St Lawrence; Emmanuelle Grillon; Alan P Koretsky; Michel Décorps
Journal:  Magn Reson Med       Date:  2002-06       Impact factor: 4.668

2.  In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy.

Authors:  M Neeman; H Dafni; O Bukhari; R D Braun; M W Dewhirst
Journal:  Magn Reson Med       Date:  2001-05       Impact factor: 4.668

3.  Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.

Authors:  J R Griffiths; D J McIntyre; F A Howe; P M McSheehy; L M Rodrigues; P Wadsworth; N M Price; F Lofts; G Nicholson; K Smid; P Noordhuis; G J Peters; M Stubbs
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

4.  Enhanced uptake of ifosfamide into GH3 prolactinomas with hypercapnic hyperoxic gases monitored in vivo by (31)P MRS.

Authors:  Loreta M Rodrigues; Simon P Robinson; Paul M J McSheehy; Marion Stubbs; John R Griffiths
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

5.  Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis.

Authors:  Jens Rengelshausen; William E Hull; Vedat Schwenger; Christoph Göggelmann; Ingeborg Walter-Sack; Jürgen Bommer
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

6.  Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma.

Authors:  Y J Kamm; A Heerschap; D J Wagener
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

7.  Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.

Authors:  J A Van Laar; Y M Rustum; C L Van der Wilt; K Smid; C M Kuiper; H M Pinedo; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 8.  Expression of hypoxia-inducible factor 1: mechanisms and consequences.

Authors:  G L Semenza
Journal:  Biochem Pharmacol       Date:  2000-01-01       Impact factor: 5.858

9.  Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry.

Authors:  Simon P Robinson; Paul F J W Rijken; Franklyn A Howe; Paul M J McSheehy; Boudewijn P J van der Sanden; Arend Heerschap; Marion Stubbs; Albert J van der Kogel; John R Griffiths
Journal:  J Magn Reson Imaging       Date:  2003-04       Impact factor: 4.813

10.  Effects of nicotinamide and carbogen on tumour oxygenation, blood flow, energetics and blood glucose levels.

Authors:  S P Robinson; F A Howe; M Stubbs; J R Griffiths
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  6 in total

Review 1.  New frontiers and developing applications in 19F NMR.

Authors:  Jian-Xin Yu; Rami R Hallac; Srinivas Chiguru; Ralph P Mason
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2012-11-02       Impact factor: 9.795

2.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 3.  High-field small animal magnetic resonance oncology studies.

Authors:  Louisa Bokacheva; Ellen Ackerstaff; H Carl LeKaye; Kristen Zakian; Jason A Koutcher
Journal:  Phys Med Biol       Date:  2013-12-30       Impact factor: 3.609

4.  Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?

Authors:  Dominick J O McIntyre; Franklyn A Howe; Christophe Ladroue; Fiona Lofts; Marion Stubbs; John R Griffiths
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-07       Impact factor: 3.333

Review 5.  How to Modulate Tumor Hypoxia for Preclinical In Vivo Imaging Research.

Authors:  Sven De Bruycker; Christel Vangestel; Steven Staelens; Tim Van den Wyngaert; Sigrid Stroobants
Journal:  Contrast Media Mol Imaging       Date:  2018-10-18       Impact factor: 3.161

6.  Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI.

Authors:  G Gambarota; W Leenders; C Maass; P Wesseling; B van der Kogel; O van Tellingen; A Heerschap
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.